← Back to Screener
Kodiak Sciences Inc Common Stock (KOD)
Price$31.05
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)27.19%
Price vs S&P 500 (4W)-24.28%
VGM Score75.65
Market Capitalization$1.94B
All Metrics
Book Value / Share (Quarterly)$1.80
P/TBV (Annual)0.32x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.38
Price vs S&P 500 (YTD)2.89%
EPS (TTM)$-4.17
10-Day Avg Trading Volume0.72M
EPS Excl Extra (TTM)$-4.17
EPS (Annual)$-4.32
ROI (Annual)-146.12%
Cash / Share (Quarterly)$2.73
ROA (Last FY)-65.42%
EBITD / Share (TTM)$-3.92
ROE (5Y Avg)-95.63%
Cash Flow / Share (Annual)$-2.21
P/B Ratio17.33x
P/B Ratio (Quarterly)21.14x
Net Income / Employee (Annual)$-1,854,600
Net Interest Coverage (TTM)-10.74x
ROA (TTM)-81.48%
EPS Incl Extra (Annual)$-4.32
Current Ratio (Annual)4.72x
Quick Ratio (Quarterly)3.42x
3-Month Avg Trading Volume0.96M
52-Week Price Return692.09%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.76
52-Week High$47.84
EPS Excl Extra (Annual)$-4.32
CapEx CAGR (5Y)-40.87%
26-Week Price Return35.12%
Quick Ratio (Annual)4.61x
13-Week Price Return23.41%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.54x
Enterprise Value$1.77B
Book Value / Share Growth (5Y)-31.46%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.40
3-Month Return Std Dev166.44%
Net Income / Employee (TTM)$-1,860,200
ROE (Last FY)-146.12%
Net Interest Coverage (Annual)-12.90x
EPS Basic Excl Extra (Annual)$-4.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.17
ROI (TTM)-253.85%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$8.33
Price vs S&P 500 (52W)667.73%
Year-to-Date Return11.05%
5-Day Price Return-15.88%
EPS Normalized (Annual)$-4.32
ROA (5Y Avg)-50.38%
Month-to-Date Return-15.42%
Cash Flow / Share (TTM)$-4.89
EBITD / Share (Annual)$-4.06
LT Debt / Equity (Annual)0.64x
ROI (5Y Avg)-95.63%
LT Debt / Equity (Quarterly)0.64x
EPS Basic Excl Extra (TTM)$-4.17
P/TBV (Quarterly)0.46x
P/B Ratio (Annual)10.85x
Book Value / Share (Annual)$2.55
Price vs S&P 500 (13W)15.16%
Beta2.24x
Revenue / Share (TTM)$0.00
ROE (TTM)-253.85%
52-Week Low$3.43
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.94est. -1.02
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.09
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KODKodiak Sciences Inc Common Stock | — | — | B | $31.05 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Kodiak Sciences is a biopharmaceutical company developing novel therapeutics for high-prevalence retinal diseases, with a focus on wet age-related macular degeneration. The company's clinical-stage pipeline includes an antibody biopolymer conjugate for previously untreated wet AMD patients, along with additional candidates such as Tarcocimab tedromer, KSI-501, and KSI-101. These programs target significant unmet needs in retinal disease treatment.